Publication | Open Access

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

MedicinePathologyClinical DermatologyPharmacotherapyAnti-cancer AgentDermatologyNonrandomized TrialCancer TreatmentOncologyAdvanced CancersErk Inhibitor